Artios: Probing DNA Damage

How Artios is attacking a different DNA damage response pathway than PARP

With programs in-licensed from Cancer Research UK and Masaryk University, Artios Pharma Ltd. thinks it has next-generation DNA damage response programs that could improve upon PARP inhibitors -- and the funds to take them to the clinic.

Artios is exploring synthetic lethal targets outside of homologous recombination, the standard repair pathway within which PARP works.

SV Health Investors helped

Read the full 571 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE